| Species |
Human |
| Protein Construction |
Integrin alpha 5 beta 1 (ITGA5 & ITGB1) Heterodimer [Phe42-Tyr995 (ITGA5) acidic tail & Gln21-Asp728 (ITGB1) basic tail]
Accession # P08648 (ITGA5) & P05556-1 (ITGB1) |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized 0.5μg AntiITGA5&ITGB1 Antibody, hFc Tag at 0.5μg/ml (100μl/Well) on the plate can bind Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer[Biotin], His & Avi, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
111.8 kDa (ITGA5) & 83.2 kDa (ITGB1) |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 110-140 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Integrin alpha 5/ beta 1, also known as VLA-5, is a widely expressed non-covalent heterodimer of a 160 kDa alpha 5 and a 130 kDa beta 1 Integrin subunit.Alpha 5/ beta 1 is up‑regulated on tumor vasculature and promotes angiogenesis. |
| Synonyms |
Integrin alpha 5 beta 1; VLA-5; ITGA5&ITGB1; Integrin alpha 5 β 1; α5β1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
